Specifically, advancements in targeting receptors like CAIX, GLUT1, and HIF within hypoxic tumor microenvironments demonstrate a shift toward precision medicine, enabling more effective targeted drug delivery systems. This evidence concerns the gene CA9 and neoplasm.